Home/Pipeline/Proprietary Pain Program(s)

Proprietary Pain Program(s)

Pain

Pre-clinicalActive

Key Facts

Indication

Pain

Phase

Pre-clinical

Status

Active

Company

Oblique Therapeutics

About Oblique Therapeutics

Oblique Therapeutics is a private, pre-revenue biotech leveraging its proprietary AbiProt® platform to generate novel antibody therapeutics against historically undruggable targets, primarily in pain and oncology. The company has validated its technology through strategic collaborations with major players like Eli Lilly and a leading animal health company. Led by an experienced team with a strong pharma background, Oblique aims to build a portfolio of assets while monetizing its platform through partnerships.

View full company profile

Therapeutic Areas

Pain Oncology

Other Pain Drugs

Drug	Company	Phase	Status
Oxycodone Patch	Avecho Biotechnology	Preclinical	Active
Oxymorphone Patch	Avecho Biotechnology	Preclinical	Active
Desmetramadol	Syntrix Pharmaceuticals	Clinical Development	Active
Diclofenac Potassium Powder for Oral Solution	Patrin Pharma	Approved	Active
CG001419	Cullgen	Phase 1	Active
Pain Management APIs	Noramco	Commercial	Active
Dipendium (Diclofenac Potassium)	NovaMedica	Approved	Active
Na ion channel TicTACs	Solu Therapeutics	Preclinical	Active
Infusional Pain Management (e.g., Paracetamol)	Galenica Senese	Commercial	Active
NCEs for Pain Management	Ipca Laboratories	Preclinical/Discovery	Active
XEN1701	Xenon Pharmaceuticals	Phase 1	Clinical trial initiated